We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Stable Abstinence Is Goal in Alcoholism Drug Trials
Stable Abstinence Is Goal in Alcoholism Drug Trials
February 18, 2009
The primary endpoint in clinical trials of drugs to treat alcoholism should be stable abstinence and prevention of relapse at two points in time — after detoxification and one year after the end of treatment — according to a draft European Medicines Agency (EMEA) guideline.